Samumed completes Phase II study for potential treatment of androgenetic alopecia
There were no serious adverse events (SAE) observed in either of the treatment groups, and the incidence of adverse events (AE) was similar between treatment and control groups.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.